Biotron Limited (ASX:BIT)
Biotron Limited is a biotechnology company. The Company is engaged in the funding and management of intermediate, and applied biotechnology research and development projects. It is engaged in developing small molecule antiviral therapeutics targeting a range of viruses including Hepatitis C virus (HCV) and human immunodeficiency virus-1 (HIV-1). The Company's lead drug, BIT225 is in Phase II clinical development for the treatment of HIV-1 and HCV infections. BIT225 is a small-molecule anti-viral compound that works to inhibit the viroporin mechanism of Viral Protein U (Vpu). BIT225, in HIV-1, offers eradicate reservoirs of virus found in long-lived macrophage cells, which contribute to the need for life-long treatment with antiretroviral drugs. For HCV, BIT225 offers as a class of oral direct-acting antiviral (DAA) drug. The Company progresses its Hepatitis B virus (HBV) program. It also designs and develops drugs drugs that target a class of viral proteins known as viroporins.